175-OR: Level 3 Hypoglycemia in Diabetes—An Age-Old but Not (Just) Old-Age Problem (iNPHORM, USA)

Introduction 65 vs ≥65 y.o. (α=0.05). Results: N=978 were analyzed (T1DM: 16.7%; male: 49.6%; retention rate: 80.1%). The mean age was 51.0 (SD:14.3) (T1DM: 44.6 SD:13.8; T2DM: 52.2 SD:14.1) years; 20.4% (T1DM: 9.8%; T2DM: 22.5%) were ≥65 y.o. Level 3 SH incidence proportions were 44.2% (≥65 y.o.: 43.8%) in T1DM, and 31.8% (≥65 y.o.: 16.4%) in T2DM. Rates were 3.6 events per person-year (EPPY) (≥65 y.o.: 2.0 EPPY) in T1DM, and 5.3 EPPY (≥65 y.o.: 0.8 EPPY) in T2DM. The interaction term (65 vs ≥65 y.o.) was statistically significant for T1DM (p=0.03) and T2DM (p0.001). In T1DM, a 5-year increase in age reduced Level 3 SH rates by 23% (95%CI: 16%-30%, p0.001) for those 65 y.o., and increased rates by 51% (95%CI: -15%-170%, p=0.16) for those ≥65 y.o. In T2DM, event rates decreased by 41% (95%CI: 38%-43%, p0.001) for those 65 y.o., and increased by 21% (95%CI: -7%-57%, p=0.15) for those ≥65 y.o. Conclusion: Level 3 SH rates declined with age until 65 y.o., when rates began to increase. Our results emphasize the need for age-specific hypoglycemia prevention. Clinical efforts should address the impact of advancing age among older adults, particularly those with T1DM; yet interventions targeting young adults, especially with T2DM, should not be overlooked. Disclosure A. Ratzki-Leewing: Research Support; Sanofi. Advisory Panel; Dexcom, Inc. Consultant; Abbott. Advisory Panel; Sanofi-Aventis U.S. Other Relationship; American Diabetes Association. Consultant; Novo Nordisk, Eli Lilly and Company. J.E. Black: None. G. Zou: None. B.L. Ryan: None. S.B. Harris: Consultant; Abbott. Research Support; Boehringer-Ingelheim. Consultant; Dexcom, Inc. Advisory Panel; Eli Lilly and Company. Consultant; Eli Lilly and Company, Novo Nordisk, Sanofi. Research Support; Novartis AG. Consultant; Bayer Inc. Funding The iNPHORM study was funded through an investigator-initiated grant from Sanofi Global.